Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (Nasdaq: CSTL) is a diagnostics company focused on molecular tests that guide patient care in dermatologic and gastroenterological disease. The CSTL news feed highlights company announcements, clinical data, financial results and corporate updates that shape how investors and clinicians view its role in precision medicine.
Readers can follow news on Castle’s core test portfolio, including DecisionDx-Melanoma for cutaneous melanoma, TissueCypher Barrett’s Esophagus, DecisionDx-SCC for high-risk cutaneous squamous cell carcinoma, MyPath Melanoma and its suite of tests for uveal melanoma such as DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq. Coverage also includes updates on AdvanceAD-Tx, the company’s gene expression profile test designed to guide systemic treatment decisions in moderate-to-severe atopic dermatitis.
In addition to product and clinical evidence updates, CSTL news items feature quarterly and annual financial results, test volume trends for core revenue drivers, and guidance ranges reported in earnings releases. Regulatory and corporate governance developments, such as bylaw amendments disclosed in Form 8-K filings, as well as participation in healthcare and investor conferences, are also common topics.
Because Castle Biosciences emphasizes rigorous clinical validation, many news releases center on new studies, meta-analyses and expert consensus papers that evaluate the performance of its tests in real-world and prospective cohorts. These articles provide insight into how DecisionDx-Melanoma, TissueCypher and other assays are being integrated into clinical decision-making.
For investors, clinicians and researchers tracking CSTL, this news page offers a centralized view of earnings announcements, product launches, reimbursement developments, clinical data presentations and corporate events related to Castle Biosciences’ molecular diagnostics business.
Castle Biosciences (CSTL) announced a collaboration with Miss America 2020, Camille Schrier, to promote its IDgenetix® genetic testing for mental health treatment. The test aims to enhance treatment outcomes by tailoring medications based on genetic profiles. Schrier shared her personal experience, indicating a potential improvement in her medication efficacy through IDgenetix. A randomized controlled trial showed that patients using IDgenetix had more than 2.5 times better remission rates than those who did not undergo genetic testing. This initiative coincides with Mental Health Awareness Month.
Castle Biosciences, Inc. (CSTL) is collaborating with the Melanoma Research Foundation and The Skin Cancer Foundation to support skin cancer research and advocacy during Skin Cancer Awareness Month in May. Skin cancer remains the most common cancer in the U.S., with an estimated one in five Americans developing it by age 70. Castle's efforts include sponsorship of educational events and fundraising activities to enhance awareness and treatment options. The company emphasizes its commitment to improving skin cancer patient outcomes through innovative diagnostic tests and partnerships.
Castle Biosciences announced an expansion of its U.S. Federal Supply Schedule contract, effective April 15, 2022, to include its entire skin cancer test portfolio. This includes DecisionDx®-SCC, DecisionDx® DiffDx™-Melanoma, myPath® Melanoma, and DecisionDx®-CMSeq, alongside the already covered DecisionDx®-Melanoma. Veterans and families treated at Veterans Health Administration facilities will benefit from increased access to these tests, which aim to enhance skin cancer diagnosis and management.
Castle Biosciences (CSTL) announced a peer-reviewed study published in Clinical Gastroenterology and Hepatology, demonstrating that their TissueCypher test significantly enhances predictions for patients with Barrett's esophagus at risk of developing esophageal cancer.
The study included data from 552 patients, revealing that 51.8% of those diagnosed as non-dysplastic progressed to high-grade dysplasia or cancer. TissueCypher outperformed traditional evaluations, supporting its integration into clinical practice for better risk management.
Castle Biosciences has acquired AltheaDx, enhancing its portfolio with the IDgenetix test, which now covers seven additional mental health conditions. This acquisition expands Castle's estimated U.S. total addressable market (TAM) by approximately $5 billion to $8 billion. The transaction includes $65 million in initial consideration, with potential future payments of up to $75 million based on performance milestones.
Castle Biosciences, Inc. (NASDAQ: CSTL) will release its financial results for Q1 2022 on May 9, 2022, after market close. A conference call to discuss these results is scheduled for 4:30 p.m. ET on the same day. The company focuses on innovative diagnostic tests for diseases like skin cancers and has ongoing R&D for treatments in psoriasis and related conditions. Investors are encouraged to join the call and can access a webcast through the company's website.
Castle Biosciences (NASDAQ: CSTL) announced a study showing that melanoma patients tested with DecisionDx-Melanoma had a 27% improvement in melanoma-specific survival compared to those who were not tested. The study, part of a collaboration with the National Cancer Institute, analyzed data from 3,261 tested patients against 10,863 untested ones. Results indicated that the DecisionDx-Melanoma test delivers valuable risk stratification, aiding in personalized treatment and potentially improving patient outcomes. The findings will be presented at the 18th European Association of Dermato Oncology Congress.
Castle Biosciences (CSTL) announced the presentation of its skin cancer gene expression profile tests at the 18th European Association of Dermato Oncology Congress in Seville, Spain, from April 21-23, 2022. Key presentations include data on the 31-gene test for melanoma, the 40-gene test for high-risk squamous cell carcinoma, and advancements in diagnostic testing for melanocytic lesions, showcasing significant improvements in survival outcomes and diagnostic accuracy. These innovations aim to enhance patient management and treatment decisions.
Castle Biosciences (Nasdaq: CSTL) presented data at the RAD Conference demonstrating that its non-invasive skin scraping technique effectively collects RNA for gene expression analysis in inflammatory skin diseases, including psoriasis and atopic dermatitis. The study, involving a sample of 40 patients, highlighted a >0.99 correlation in RNA yield, suggesting reliability for future tests. Castle's ongoing 4,800 patient study aims to validate a gene expression profile test, with initial results expected in 2023 and potential launch by 2025, addressing a significant need for personalized medication selection.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that CEO Derek Maetzold and CFO Frank Stokes will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. Eastern time. The presentation can be accessed via a live audio webcast on the company's website, with a replay available for two weeks afterward. Castle Biosciences focuses on innovative diagnostic tests for conditions like skin cancers and Barrett’s esophagus, aiming to improve patient care.